Syndax Pharmaceuticals Stock (NASDAQ: SNDX)

Syndax Pharmaceuticals

SYNDAX PHARMACEUTICALS INC

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Stock market trader

Analyst Color

Biotech

News

Analyst Ratings

General

SNDX

JP Morgan raised Syndax&#39;s price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

Syndax&#39;s Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth

Roku.Shutterstock

Price Target

Pre-Market Outlook

Markets

Trading Ideas

ADSK

BELFB

COIN

PEPG

PLUG

ROKU

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

Health Care

Movers

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025.

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals Inc

Press Releases

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Syndax Announces Participation in February Investor Conferences

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Legal

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Syndax Announces Participation in March Investor Conferences

Earnings

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

INCY

Ardelyx

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dyne Therapeutics

89bio

Geron

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

ARS Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Zymeworks

JP Morgan

Citigroup

HC Wainwright & Co.

Scotiabank

Goldman Sachs

Comments

Syndax Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga